LONDON, UK / ACCESSWIRE / February 01, 2018 / Active-Investors.com has just released a free research report on Madrigal Pharma, Inc. (NASDAQ: MDGL). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=MDGL as the Company's latest news hit the wire. On January 30, 2018, the Company, which is a clinical-stage biopharmaceutical organization, declared that the Week 12 Phase-2 results for its thyroid hormone receptor MGL-3196 will be presented during a main plenary session at the Annual Meeting of the European Association for the Study of the Liver (EASL) at The International Liver Congress? 2018, which is to be held in Paris, France, from April 11 to April 15, 2018. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Madrigal Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=MDGL

Overview of the Presentation

The presentation will include results from an ongoing Phase-2 clinical trial for evaluating MGL-3196 in patients with biopsy-proven non-alcoholic steatohepatitis (NASH).

Stephen Harrison, M.D., Principal Investigator of the study, and Medical Director for Pinnacle Clinical Research, San Antonio, Texas, and Visiting Professor of Hepatology, Oxford University, will make the presentation on behalf of Madrigal Pharma on April 13, 2018. The abstract for this presentation is entitled, ?GS2 MGL-3196, a selective thyroid hormone receptor-beta agonist significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36-week serial liver biopsy study'. The abstract would be available on March 28, 2018, at 10:00 am CET.

MGL-3196, THR ?-Selective Agonist

The thyroid hormone plays a very important role in controlling lipid metabolism by activating its beta-receptor. It affects several health parameters such as levels of serum cholesterol and triglycerides, and the pathological buildup of fat in the liver. However, most of the attempts to use this pathway for therapeutic purposes in cardio-metabolic and liver diseases have been obstructed by the lack of selectivity of older compounds for the thyroid hormone receptor (THR)-?, chemically related toxicities and undesirable distribution in the body.

Madrigal Pharma discovered that greater selectivity for thyroid hormone receptor (THR)-? and liver targeting might overcome these challenges and deliver the full therapeutic potential of THR-? agonism. Thus, the Company developed MGL-3196, which is a first-in-class, orally-administered, small-molecule, liver-directed, THR ?-selective agonist. MGL-3196 has proven to have a wide range of therapeutically beneficial effects, improving components of both metabolic syndrome, such as insulin resistance and dyslipidemia, and fatty liver disease, including lipotoxicity and inflammation. It also has an excellent safety profile. This suggests that MGL-3196 could be the preferred treatment option for NASH.

About the Ongoing Phase-2 NASH Study

The ongoing Phase-2 study is a randomized, double blind, placebo-controlled, multi-center study. It enrolled 125 patients of 18 years of age and older with liver biopsy-confirmed NASH and included approximately 25 clinical sites in the United States.

In this study, patients were randomized to receive either placebo or MGL-3196 with twice as many patients receiving MGL-3196 as placebo.

Primary Endpoint Achieved

  • MGL-3196 exhibited statistically significant results for the primary endpoint, i.e. the reduction of liver fat at 12 weeks compared to baseline (relative change), assessed by MRI-PDFF, which is a non-invasive imaging test.
  • The liver fat was reduced by 36.3% and 42.0% relative reduction in MGL-3196 treated patients, e.g., all MGL-3196 treated patients (78) and all high exposure MGL-3196 treated patients (44/78), respectively, compared to a 9.6% median reduction in liver fat in 38 placebo-treated patients. It must be noted that these results were statistically significant (p<0.0001) for both MGL-3196 treatment groups.
  • Besides, MGL-3196 was well-tolerated. Some serious adverse events were noted during the 12-week portion of the study but none were related to MGL-3196.

Remaining Results Expected in Second Half of 2018

  • The additional efficacy endpoints for the study are being evaluated in the 36-week treatment period by repeat MRI-PDFF and conventional liver biopsy to assess histologic evidence for the resolution and improvement in NASH. The results for the 36-week endpoints are expected by the second quarter of 2018.
  • The study remains blinded. Thus, some patients (who are blinded as to whether they were on placebo or MGL-3196 in the main 36-week portion of the study) are receiving extended treatment beyond 36 weeks for up to 36 additional weeks, on the basis of the liver enzyme inclusion criteria.
  • All patients in the extension study will be administered MGL-3196 and only non-invasive assessments will be made, such as serial MRI-PDFF, safety labs, and circulating biomarkers.

Stock Performance Snapshot

January 31, 2018 - At Wednesday's closing bell, Madrigal Pharma's stock advanced 6.13%, ending the trading session at $148.42.

Volume traded for the day: 448.77 thousand shares, which was above the 3-month average volume of 203.99 thousand shares.

Stock performance in the last month ? up 61.70%; previous three-month period ? up 223.57%; past twelve-month period ? up 871.34%; and year-to-date - up 61.70%

After yesterday's close, Madrigal Pharma's market cap was at $2.13 billion.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors